ATE458000T1 - Zielgerichtete fusionsproteine für die krebstherapie - Google Patents
Zielgerichtete fusionsproteine für die krebstherapieInfo
- Publication number
- ATE458000T1 ATE458000T1 AT06821700T AT06821700T ATE458000T1 AT E458000 T1 ATE458000 T1 AT E458000T1 AT 06821700 T AT06821700 T AT 06821700T AT 06821700 T AT06821700 T AT 06821700T AT E458000 T1 ATE458000 T1 AT E458000T1
- Authority
- AT
- Austria
- Prior art keywords
- moiety
- cancer
- apoptosis
- fusion proteins
- cell
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 3
- 102000035195 Peptidases Human genes 0.000 abstract 2
- 230000001640 apoptogenic effect Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 abstract 1
- 102000028517 Neuropeptide receptor Human genes 0.000 abstract 1
- 108070000018 Neuropeptide receptor Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 abstract 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3084DE2005 | 2005-11-18 | ||
| PCT/IN2006/000452 WO2007057922A1 (en) | 2005-11-18 | 2006-11-16 | Targeted fusion proteins for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE458000T1 true ATE458000T1 (de) | 2010-03-15 |
Family
ID=37772861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06821700T ATE458000T1 (de) | 2005-11-18 | 2006-11-16 | Zielgerichtete fusionsproteine für die krebstherapie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100184651A1 (de) |
| EP (1) | EP1957524B1 (de) |
| AT (1) | ATE458000T1 (de) |
| AU (1) | AU2006314037B2 (de) |
| CA (1) | CA2630012A1 (de) |
| DE (1) | DE602006012358D1 (de) |
| WO (1) | WO2007057922A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8178495B2 (en) | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
| JP2009525946A (ja) | 2005-12-20 | 2009-07-16 | デューク・ユニヴァーシティ | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| DE102007042107B4 (de) * | 2007-09-05 | 2010-07-15 | Siemens Ag | Pharmazeutische Zusammensetzung mit eisenbindendem Agens |
| CN102177174B (zh) * | 2008-05-14 | 2015-06-03 | 分子基术事业化集团(株) | 用于靶向凋亡细胞的肽及其用途 |
| CN102149680B (zh) * | 2008-07-08 | 2014-12-10 | 第一三共株式会社 | 含氮芳族杂环化合物 |
| JP5801807B2 (ja) * | 2009-08-14 | 2015-10-28 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 修飾された血管作動性腸管ペプチド |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| ES2669190T3 (es) | 2011-06-06 | 2018-05-24 | Phasebio Pharmaceuticals, Inc. | Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2015134833A2 (en) * | 2014-03-07 | 2015-09-11 | Proda Biotech Llc | Therapeutic proteins for treating cancers and methods for using such proteins |
| WO2015172046A1 (en) | 2014-05-08 | 2015-11-12 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| AU2016215604B2 (en) | 2015-02-02 | 2020-08-13 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| WO2016130518A2 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| EP3903818A1 (de) | 2015-11-19 | 2021-11-03 | Revitope Limited | Komplementierung eines funktionellen antikörperfragments für ein zwei-komponenten-system zur umgelenkten tötung unerwünschter zellen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803358B1 (en) * | 2000-04-14 | 2004-10-12 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| EP0977862B8 (de) * | 1997-04-30 | 2009-09-16 | Twinstrand Therapeutics Inc. | Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen |
| AU2003267124A1 (en) * | 2002-09-09 | 2004-03-29 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| WO2006099590A2 (en) * | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
-
2006
- 2006-11-16 AT AT06821700T patent/ATE458000T1/de not_active IP Right Cessation
- 2006-11-16 WO PCT/IN2006/000452 patent/WO2007057922A1/en not_active Ceased
- 2006-11-16 AU AU2006314037A patent/AU2006314037B2/en not_active Ceased
- 2006-11-16 CA CA002630012A patent/CA2630012A1/en not_active Abandoned
- 2006-11-16 DE DE602006012358T patent/DE602006012358D1/de active Active
- 2006-11-16 EP EP06821700A patent/EP1957524B1/de active Active
- 2006-11-16 US US12/093,697 patent/US20100184651A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1957524A1 (de) | 2008-08-20 |
| CA2630012A1 (en) | 2007-05-24 |
| WO2007057922A1 (en) | 2007-05-24 |
| AU2006314037A1 (en) | 2007-05-24 |
| EP1957524B1 (de) | 2010-02-17 |
| AU2006314037B2 (en) | 2010-09-23 |
| DE602006012358D1 (de) | 2010-04-01 |
| US20100184651A1 (en) | 2010-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006012358D1 (de) | Zielgerichtete fusionsproteine für die krebstherapie | |
| MX348047B (es) | Proteinas de fusion terapeuticas. | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| MX2009013372A (es) | Proteinas de fusion bifuncionales de la hormona estimulante de alfa-melanocitos (alfa-msh) y proteina natriuretica atrial (anp) y usos en hipertension y lesion de riñon aguda. | |
| NZ599204A (en) | High affinity human antibodies to human protease-activated receptor-2 | |
| JP2016538240A5 (de) | ||
| MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
| GEP20115324B (en) | Tweak binding antibodies | |
| WO2006126102A8 (en) | Compositions and methods for fusion protein separation | |
| PH12017500866A1 (en) | Targeted xten conjugate compositions and methods of making same | |
| NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| MX2009003126A (es) | Agente para prevenir/tratar el cancer. | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| MY192113A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| EP2403871A4 (de) | Für missgefaltetes prionenprotein spezifische antikörper und epitope | |
| UY30324A1 (es) | Proteinas de fusion del rage, formulaciones y métodos de uso | |
| CL2008001661A1 (es) | Proteina de fusion que comprende un peptido natriuretico y un dominio fc de un anticuerpo; molecula de acido nucleico que la codifica; composicion farmaceutica que la comprende; y su uso para tratar enfermedades asociadas con la actividad diuretica, natriuretica y vasodilatadora anomala. | |
| CL2012000063A1 (es) | Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07). | |
| EP2352523A4 (de) | Verbesserte anti-cd19-antikörper | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| GB2431583A (en) | Combination therapy using transferrin fusion proteins comprising GLP-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |